LexAurum Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

LexAurum Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-533	Closed	-$3.78K	–	372
2025 Q1	$3.78K	Hold	533	–	–	﹤0.01%	346
2024 Q4	$11.7K	Hold	533	–	–	﹤0.01%	334
2024 Q3	$10.7K	Hold	533	–	–	﹤0.01%	315
2024 Q2	$9.28K	Hold	533	–	–	﹤0.01%	297
2024 Q1	$22.2K	Hold	533	–	–	0.01%	298
2023 Q4	$13.4K	Hold	533	–	–	﹤0.01%	297
2023 Q3	$17.4K	Hold	533	–	–	0.01%	284
2023 Q2	$31K	Hold	533	–	–	0.01%	269
2023 Q1	$13.9K	Hold	533	–	–	﹤0.01%	253
2022 Q4	$15.9K	Hold	533	–	–	0.01%	248
2022 Q3	$27K	Buy	+533	New	+$18.4K	0.01%	239

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LexAurum Advisors's XFOR Position: Q2 2025 in Review

LexAurum Advisors sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 533 shares — an estimated $3.78K sold.

LexAurum Advisors first reported a position in XFOR in Q3 2022 and held it in 11 quarters. The position peaked at $31K in Q2 2023. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

LexAurum Advisors reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
LexAurum Advisors sold 533 X4 Pharmaceuticals shares in Q2 2025, an estimated $3.78K.
LexAurum Advisors first reported a position in X4 Pharmaceuticals in Q3 2022 and held it in 11 quarters.
LexAurum Advisors's X4 Pharmaceuticals position peaked at $31K in Q2 2023.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on LexAurum Advisors's 13F filing for Q2 2025, filed 17 Jul 2025.